-- Robert Preidt
THURSDAY, March 28 (HealthDay News) -- A new drug called
Tecfidera has been approved to treat adults with relapsing forms of
multiple sclerosis, the U.S. Food and Drug Administration said
The approval is based on the results of two clinical trials
showing that patients who took Tecfidera (dimethyl fumarate)
capsules had fewer MS relapses than those who took an inactive
placebo. One of the trials also showed that a worsening of
MS-related disability occurred less often in patients who took the
drug than in those who took the placebo.
"Tecfidera will be a welcome addition to the growing list of agents that alter the course of multiple sclerosis," said one expert, Dr. Fred Lublin, director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York City.
"Based on the clinical trial data available, this new agent has very impressive efficacy data and a good safety profile," he added.
The FDA said that Tecfidera may lower levels of white blood
cells, which help protect the body from infection. Lower levels of
white blood cells may increase the risk of infection, but no
significant increase in infections occurred in patients taking the
Before starting treatment with Tecfidera, and each year after,
doctors should check patients' white blood cell counts, the FDA
Flushing (warmth and redness), nausea, vomiting and diarrhea
were the most common side effects in patients taking the drug,
especially at the start of treatment with Tecfidera, which is made
by Biogen Idec in Massachusetts.
"No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients," Dr. Russell Katz, director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.
"Multiple sclerosis can impair movement, sensation and thinking, and have a profound impact on a person's quality of life," he added.
MS is an autoimmune disease of the central nervous system that
disrupts communication between the brain and other parts of the
body, resulting in problems such as muscle weakness and difficulty
with coordination and balance.
For most MS patients, periods of worsening disability (relapses)
are initially followed by recovery periods (remissions). Over time,
these recovery periods may be incomplete, resulting in a
progressive increase in disability.
The U.S. National Institute of Neurological Disorders and Stroke
has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.